Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Aimee Ginsburg Arlen"'
Autor:
Michele O'Brien, Jacqueline D. Foster, Kimberly Ness, Rowena Schwartz, Aimee Ginsburg Arlen, Carrie Tompkins Stricker
Publikováno v:
Clinical journal of oncology nursing.
Nurses have an important role in the development, implementation, and evaluation of cancer survivorship programs. Growing numbers of cancer survivors challenge community oncology practices to incorporate survivorship care according to new standards a
Autor:
Aimee Ginsburg Arlen, Cynthia Taniguchi, J. Russell Hoverman, Susan Ash-Lee, Deb Harrison, Sabrina Q. Mikan, Kevin Donald Olson
Publikováno v:
Journal of Clinical Oncology. 31:22-22
22 Background: Addressing advance care planning (ACP) early in metastatic disease is a challenge for providers across oncology. Providing a systematic method to engage providers and patients in these discussions offers opportunities to improve end of
Autor:
Aimee Ginsburg Arlen, Sabrina Q. Mikan, Kevin Donald Olson, Susan Ash-Lee, J. Russell Hoverman, Cynthia Taniguchi, Deb Harrison
Publikováno v:
Journal of Clinical Oncology. 31:99-99
99 Background: Patients, families and healthcare providers can be apprehensive about having end-of-life (EOL) conversations. However, asking patients about personal values regarding their healthcare goals may create a platform for more in depth conve
Autor:
Cynthia Taniguchi, Susan Ash-Lee, Kevin Donald Olson, Deb Harrison, Sabrina Q. Mikan, J. Russell Hoverman, Aimee Ginsburg Arlen
Publikováno v:
Journal of Clinical Oncology. 31:243-243
243 Background: Comprehensive cancer care embraces the concept of having timely discussions with patients about end of life care preferences regarding treatment interventions. Physicians and healthcare teams are frequently challenged with identifying
Updated use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine
Autor:
Thomas H. Cartwright, Aimee Ginsburg Arlen, Lalan S. Wilfong, Robyn K. Harrell, J. Russell Hoverman, Roy A. Beveridge
Publikováno v:
Journal of Clinical Oncology. 31:6607-6607
6607 Background: Pancreatic cancer (PC) is the fourth leading cause of death in the United States. It is estimated that 45,220 patients will be diagnosed in 2013 and 38,460 will die (Siegel, CA Cancer J Clin 2013). Gemcitabine has long been the stand
Autor:
Debra A. Patt, Asif Ahmad, Roy A. Beveridge, Madeline Nubie, Denise R. Kazzaz, Leslie T. Busby, Aimee Ginsburg Arlen, Mark A. Sitarik
Publikováno v:
Journal of Clinical Oncology. 30:294-294
294 Background: Electronic health records (EHR) provide opportunities for quality enhancements at various points in care. It can support electronic orders, meaningful use, progress notes, medication and allergy data, electronic prescribing, and vital
Autor:
Jackie Foster, Aimee Ginsburg Arlen, Michele O'Brien, Mark D. Sborov, Kimberly Ness, Rowena Schwartz
Publikováno v:
Journal of Clinical Oncology. 30:33-33
33 Background: Each of the 12 million cancer survivors in the United States has unique needs, giving oncology providers the opportunity to address survivorship issues and optimize care. Minnesota Oncology, a community oncology practice, has implement
Autor:
Carla Butler-Dorian, Roy A. Beveridge, J. Russell Hoverman, Janet L. Espirito, Thomas H. Cartwright, Jennifer Flinn, Marcus A. Neubauer, Debra A. Patt, M. Clayton, Sheetal Sheth, Greg C. Nelson, Aimee Ginsburg Arlen, Jody S. Garey, Leslie T. Busby, Brian Turnwald
Publikováno v:
Journal of Clinical Oncology. 30:65-65
65 Background: Several organizations have created oncology pathways (pws) to support evidence-based medicine, and both standardize and improve the quality of care. Information is scarce; however, regarding the requirements for successful implementati
Autor:
Thomas H. Cartwright, Lalan S. Wilfong, Roy A. Beveridge, Robyn K. Harrell, Aimee Ginsburg Arlen, J. Russell Hoverman
Publikováno v:
Journal of Clinical Oncology. 30:e16536-e16536
e16536 Background: Pancreatic cancer (PC) is the fourth leading cause of death in the United States. It is estimated that 43,920 patients will be diagnosed in 2012 and 37,390 will die (Siegel, CA Cancer J Clin, 2012). Gemcitabine has long been the st
Autor:
O'Brien, Michele1, Stricker, Carrie Tompkins2, Foster, Jacqueline D.3, Ness, Kimberly4, Arlen, Aimee Ginsburg5, Schwartz, Rowena N.5
Publikováno v:
Clinical Journal of Oncology Nursing. Feb2014 Supplement, Vol. 18, p9-14. 6p. 2 Charts.